Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Abstract: Some embodiments provide a method for identifying network architecture in a datacenter. The method identifies connection information for multiple network elements. The connection information for each network element specifies other network elements to which the network element connects. The method assigns a set of the network elements to a set of two or more layers based on the connection information for the network element. The method uses the connection information to identify at least one group of network elements organized into a particular network architecture. The identified groups are for use in displaying user interface visualizations of the network elements of the datacenter.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: Some embodiments provide a method for identifying network architecture in a datacenter. The method identifies connection information for multiple network elements. The connection information for each network element specifies other network elements to which the network element connects. The method assigns a set of the network elements to a set of two or more layers based on the connection information for the network element. The method uses the connection information to identify at least one group of network elements organized into a particular network architecture. The identified groups are for use in displaying user interface visualizations of the network elements of the datacenter.

Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 and Compound 2 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Abstract: Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Abstract: Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Abstract: In one example, a management node may include a storage device to store network device information associated with a plurality of network devices and physical hosts in a datacenter. Example network device information may include at least one of routing information and media access control (MAC) address information. Further, the management node may include a processor operable with the storage device and memory coupled to the processor. In one example, the memory may include a network topology generation unit to determine adjacency between the plurality of network devices in the datacenter using the routing information and/or media access control (MAC) address information associated with the plurality of network devices and generate a network topology including a network path between a source endpoint and a destination endpoint using the adjacency between the plurality of network devices.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: In one example, a management node may include a storage device to store network device information associated with a plurality of network devices and physical hosts in a datacenter. Example network device information may include at least one of routing information and media access control (MAC) address information. Further, the management node may include a processor operable with the storage device and memory coupled to the processor. In one example, the memory may include a network topology generation unit to determine adjacency between the plurality of network devices in the datacenter using the routing information and/or media access control (MAC) address information associated with the plurality of network devices and generate a network topology including a network path between a source endpoint and a destination endpoint using the adjacency between the plurality of network devices.

Abstract: Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.